1. Home
  2. BGMS vs BIAF Comparison

BGMS vs BIAF Comparison

Compare BGMS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio Green Med Solution Inc.

BGMS

Bio Green Med Solution Inc.

HOLD

Current Price

$0.92

Market Cap

5.6M

Sector

N/A

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$15.61

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGMS
BIAF
Founded
1996
2014
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
4.5M
IPO Year
2000
2022

Fundamental Metrics

Financial Performance
Metric
BGMS
BIAF
Price
$0.92
$15.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.1K
5.6M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
$80,482.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$0.57
$0.24
52 Week High
$6.70
$13.58

Technical Indicators

Market Signals
Indicator
BGMS
BIAF
Relative Strength Index (RSI) 55.58 89.05
Support Level $0.87 $1.10
Resistance Level $1.10 N/A
Average True Range (ATR) 0.04 0.86
MACD -0.00 0.91
Stochastic Oscillator 83.81 86.56

Price Performance

Historical Comparison
BGMS
BIAF

About BGMS Bio Green Med Solution Inc.

Bio Green Med Solution Inc is engaged in the supply and trading of protective and fire safety equipment. The company distributes products such as fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel. It also provides fire safety systems, including sprinkler systems, fire alarm systems, valves, and CO2 systems. The company operates across commercial, industrial, healthcare, and residential sectors, with a focus on distribution and compliance with applicable safety standards.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: